Journal: Cell Death & Disease

Article Title: Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma

doi: 10.1038/s41419-025-07622-z

Figure Lengend Snippet: A Experimental workflow for silencing the cGAS-STING pathway and ICD in vivo studies. B , C Western blotting was used to confirm the knockout of cGAS and STING proteins in Hepa1-6 cells. D , E The proportion of mature dendritic cells (CD80 + CD86 + DCs) was assessed after treatment with the anti-CD11c antibody. F , G Western blotting was applied to confirm the reduction of ICD-related molecules (ATP, CALR, HMGB1) after treatment with the anti-CD11c antibody. H , I Phosphorylation of TBK1 and IRF3 was reduced in tumors after silencing the cGAS-STING pathway. J , K Tumors were harvested and weight was assessed, showing an increase in tumor size after silencing the cGAS-STING pathway and ICD in all five groups. L – N Flow cytometry analysis was used to evaluate the levels of functional CD8 + T cells after silencing the cGAS-STING pathway and ICD in all five groups. n = 6 per group. Error bars represent standard deviation. Ns not statistically significant. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: CD11c monoclonal antibodies (BioXCell, NH, USA) were administered intraperitoneally at 100 μg/mouse, starting 7 days before combination therapy and repeated weekly for 3 weeks.

Techniques: In Vivo, Western Blot, Knock-Out, Phospho-proteomics, Flow Cytometry, Functional Assay, Standard Deviation

Journal: Cancer letters

Article Title: EphB1 promotes the differentiation and maturation of dendritic cells in non-small cell lung cancer.

doi: 10.1016/j.canlet.2023.216567

Figure Lengend Snippet: Fig. 3. EphB1 loss compromises the differentiation and maturation of dendritic cells. (A)The percentage of DCs (defined as CD45+, CD11C+, MHCII+) in the brains of EphB1−/−mice was measured by flow cytometry. The percentage of CD11B+CD11C+ cDCs and B220+CD11C+ pDCs in bone marrow (B), spleen (C) and tumor (D) in tumor-bearing WT and KO mice was measured by flow cytometry. (N = 3) (E) The percentage of CD8+IFN-γ+ T cells in tumor-bearing mice in WT and KO mice. (N = 3) Student’s T test, *P < 0.05, **P < 0.01, NS:no significance. (F) The immunofluorescence images of EphB1 and CD11C in tumor tissues from tumor-bearing mice. The positive cells are indicated by arrows.

Article Snippet: The antibodies used for immunostaining were obtained from the following sources: CD11c (Proteintech #17342-1-AP, USA), EphB1 (Santa #5F10A4, USA) and EphB1 (phosphor-Tyr594) (Biorbvt # orb187803, UK).

Techniques: Flow Cytometry, Immunofluorescence

Journal: Cancer letters

Article Title: EphB1 promotes the differentiation and maturation of dendritic cells in non-small cell lung cancer.

doi: 10.1016/j.canlet.2023.216567

Figure Lengend Snippet: Fig. 4. EphB1 receptor tyrosine kinase mediates DC differentiation and maturation. (A)The percentage of immature DCs (defined as CD45+, CD11C+, CD11B+) and mature DCs (defined as CD45+, CD11C+, MHCII+) in bone marrow cells from EphB1 WT and KO mice was measured by flow cytometry. (N = 3) (B) The percentage of CD11C+MHCII+ and CD11C+ CD86+ DCs after treatment with LPS in bone marrow cells from EphB1 WT and KO mice. (N = 3) (C) The percentage of CD11B+CD11C+

Article Snippet: The antibodies used for immunostaining were obtained from the following sources: CD11c (Proteintech #17342-1-AP, USA), EphB1 (Santa #5F10A4, USA) and EphB1 (phosphor-Tyr594) (Biorbvt # orb187803, UK).

Techniques: Flow Cytometry

Journal: Cancer letters

Article Title: EphB1 promotes the differentiation and maturation of dendritic cells in non-small cell lung cancer.

doi: 10.1016/j.canlet.2023.216567

Figure Lengend Snippet: Fig. 5. COX-2 is implicated in DC differentiation in EphB1 KO mice. Bone marrow cells from EphB1 WT and KO mice were subjected to RNA-seq following treatment with IL-4 and GM-CSF. (A) PCA analysis. (B) The DEGs are shown in the volcano plot. (C) GO analyses of DEGs; (D) Heatmap of DEGs (above) and histogram showing the expression levels of key genes (below). The numbers indicate the q values. (E) The expression of COX2, MAPK14 and DUSP1 in EphB1-negative DCs (NEDC) compared to EphB1-positive DCs (EDC) was analyzed in publicly accessible single-cell RNA-seq (scRNA seq) datasets of lung cancer tissues (GSE 131907, GSE 139555, GSE146100, GSE 150660, GSE 176021). (F) The expression of COX2 measured by Western blot after treatment with ephrinB2-FC and EphB1-FC. (G) Cox-2 expression in KO DCs. The percentage of CD11C+MHCII+ DCs in naive bone marrow cells (H) and IL-4- and GM–CSF–treated bone marrow cells (N = 3) (I) after treatment with the COX-2 inhibitor celecoxib. (N = 3) Student’s T test, *P < 0.05, **P < 0.01, ***P < 0.001. DEGs: differentially expressed genes.

Article Snippet: The antibodies used for immunostaining were obtained from the following sources: CD11c (Proteintech #17342-1-AP, USA), EphB1 (Santa #5F10A4, USA) and EphB1 (phosphor-Tyr594) (Biorbvt # orb187803, UK).

Techniques: RNA Sequencing, Expressing, Western Blot

Journal: Cancer letters

Article Title: EphB1 promotes the differentiation and maturation of dendritic cells in non-small cell lung cancer.

doi: 10.1016/j.canlet.2023.216567

Figure Lengend Snippet: Fig. 7. TNP-000386 activates phosphorylation of EphB1 and inhibits tumor growth. An in silico docking study along with the pocket of the EphB1 kinase domain for ATP binding (PDB code:5MJA) was performed. The top three lead compounds were selected and tested for activation potency, including TANA-016837, TNP-000386 and TCD-04070014. (A) The phosphorylation of EphB1 activated by TANA-016837, TNP-000386 and TCD-04070014 was evaluated by western blot. The number above bands indicates the gray values for p-EphB1 bands normalized to the β-actin bands. (B) The percentage of CD11C+MHCII+ DCs in IL-4- and GM–CSF–induced bone marrow cells after treatment with TANA-016837, TNP-000386 and TCD-04070014. (N = 3) (C) The percentage of CD11C+CD80+ and CD11C+CD86+ mature DCs in LPS-induced bone marrow cells after treatment with TANA-016837, TNP-000386 and TCD-04070014. (N = 3); The Lewis lung cancer (LLC) cells were subcutaneously injected into C57BL/6 mice. When the tumors reached approximately 100 mm3, TNP-000386 was intraperitoneally injected into tumor-bearing mice at approximately 50 mg/kg (D)Growth curve of tumor-bearing mice; (E)Excised tumor samples; (F) The immunofluorescence images of EphB1 phosphorylation in both cancer cells and DCs.

Article Snippet: The antibodies used for immunostaining were obtained from the following sources: CD11c (Proteintech #17342-1-AP, USA), EphB1 (Santa #5F10A4, USA) and EphB1 (phosphor-Tyr594) (Biorbvt # orb187803, UK).

Techniques: Phospho-proteomics, In Silico, Binding Assay, Activation Assay, Western Blot, Injection, Immunofluorescence

Journal: International Journal of Molecular Sciences

Article Title: Ex Vivo and In Vivo Analyses of Novel 3D-Printed Bone Substitute Scaffolds Incorporating Biphasic Calcium Phosphate Granules for Bone Regeneration

doi: 10.3390/ijms22073588

Figure Lengend Snippet: Representative images of the inflammatory tissue reactions to the scaffolds within the subcutaneous connective tissue (CT) at day 15 post implantationem. ( A ) CD163 detection and ( B ) CD11c detection within the implantation beds of the PCL scaffolds combined with the BCP granules (PCL+BCP and asterisk in ( A )). ( C ) CD163 detection and ( D ) CD11c detection within the implantation beds of the pure PCL scaffolds. Red arrows = positive macrophages, white arrows = negative macrophages, red arrowheads = positive multinucleated giant cells, white arrowheads = negative multinucleated giant cells (immunostainings, 400× magnifications, scalebars = 10 µm).

Article Snippet: Two respective antibodies i.e., integrin alpha x (CD11c) (abx231412, Abbexa Ltd., Milton, UK) and hemoglobin scavenger receptor (CD163) (ab182422, abcam, Cambridge, UK) were used.

Techniques: